PT  - JOURNAL ARTICLE
AU  - Naing, Aung
AU  - Meric-Bernstam, Funda
AU  - Stephen, Bettzy
AU  - Karp, Daniel D
AU  - Hajjar, Joud
AU  - Rodon Ahnert, Jordi
AU  - Piha-Paul, Sarina A
AU  - Colen, Rivka R
AU  - Jimenez, Camilo
AU  - Raghav, Kanwal P
AU  - Ferrarotto, Renata
AU  - Tu, Shi-Ming
AU  - Campbell, Matthew
AU  - Wang, Linghua
AU  - Sabir, Sarjeel H
AU  - Tapia, Coya
AU  - Bernatchez, Chantale
AU  - Frumovitz, Michael
AU  - Tannir, Nizar
AU  - Ravi, Vinod
AU  - Khan, Saria
AU  - Painter, Jeane M
AU  - Abonofal, Abulrahman
AU  - Gong, Jing
AU  - Alshawa, Anas
AU  - McQuinn, Lacey M
AU  - Xu, Mingxuan
AU  - Ahmed, Sara
AU  - Subbiah, Vivek
AU  - Hong, David S
AU  - Pant, Shubham
AU  - Yap, Timothy A
AU  - Tsimberidou, Apostolia M
AU  - Dumbrava, Ecaterina E Ileana
AU  - Janku, Filip
AU  - Fu, Siqing
AU  - Simon, Richard M
AU  - Hess, Kenneth R
AU  - Varadhachary, Gauri R
AU  - Amir Habra, Mouhammed
TI  - Phase 2 study of pembrolizumab in patients with advanced rare cancers
AID  - 10.1136/jitc-2019-000347
DP  - 2020 Mar 01
TA  - Journal for ImmunoTherapy of Cancer
PG  - e000347
VI  - 8
IP  - 1
4099  - http://jitc.bmj.com/content/8/1/e000347.short
4100  - http://jitc.bmj.com/content/8/1/e000347.full
SO  - J Immunother Cancer2020 Mar 01; 8
AB  - Markup server — Error Not Found The page you were trying to reach could not be found. Please check the address for the page you were trying to reach. If you believe you have reached this page in error, you may contact us with any questions.